Analysts at Deutsche Bank say itâ€™s time to give a fresh look to shares of Qualcomm and Lam Research, arguing that the stocks have sold off too much amid concerns about the COVID-19 pandemic.Based on the strength of the data, a Phase 1/2a first-in-human clinical trial of the vaccine candidate, Ad26.COV2.S, in healthy volunteers, has now commenced in the United States and Belgium, the company said.